Beyond intraocular pressure: Neuroprotective strategies for future glaucoma therapy

Optometry and Vision Science

Volumn 78, Issue 2, 2001, Pages 85-94

  Hartwick, Andrew T E ^a,b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Calcium channel blockers; Excitotoxicity; Glaucoma; Glutamate; Neuroprotection; Neurotrophins; Nitric oxide

Indexed keywords

ANTIGLAUCOMA AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; NEUROTROPHIN; NITRIC OXIDE SYNTHASE INHIBITOR;

DRUG EFFICACY; DRUG MECHANISM; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOCULAR PRESSURE ABNORMALITY; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA GANGLION CELL; REVIEW; RISK FACTOR;

EID: 0035106419     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006324-200102000-00008     Document Type: Review

References (118)

1. Number of people with glaucoma worldwide
2. The probability of blindness from open-angle glaucoma
3. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture
4. Aspects of the epidemiology of chronic glaucoma
5. Intraocular pressure elevation: Cause or effect in chronic glaucoma?
6. Experimental glaucoma in the rhesus monkey
7. Chronic experimental glaucoma in primates: II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport
8. Prognostic factors in glaucomatous visual field loss
9. Long-term follow-up of treated open-angle glaucoma
10. Why do some people go blind from glaucoma?
11. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma
12. Association between intraocular pressure and loss of visual field in chronic simple glaucoma
13. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: A 15-year follow-up
14. Risk factors for the progression of treated primary open-angle glaucoma: A multivariate life-table analysis
15. Risk factors for progression of visual field defects in medically treated patients with glaucoma
16. Biostatistical evidence for two distinct chronic open angle glaucoma populations
17. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma
18. The relationship between intraocular pressure and visual field progression in glaucoma
19. Intraocular pressure as a risk factor for visual field loss in pseudoexfoliative and in primary open-angle glaucoma
20. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma
21. Early Manifest Glaucoma Trial: Design and baseline data
22. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans
23. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures
24. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma
25. Risk factors for rate of progression of glaucomatous visual field loss: A computer-based analysis
26. Glaucoma: The damage caused by pressure. XLVI Edward Jackson memorial lecture
27. Mechanisms of optic nerve damage in primary open angle glaucoma
28. Various glaucomatous optic nerve appearances: Clinical correlations
29. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss
30. Optic nerve damage in human glaucoma: II. The site of injury and susceptibility to damage
31. Retinal ganglion cell death in glaucoma: The how, the why, and the maybe
32. Neuronal death in glaucoma
33. Comparison of ganglion cell loss and cone loss in experimental glaucoma
34. Primary open-angle glaucoma is not associated with photoreceptor loss
35. Retinal ganglion cell loss is size dependent in experimental glaucoma
36. Foveal ganglion cell loss is size dependent in experimental glaucoma
37. Chronic human glaucoma causing selectively greater loss of large optic nerve fibers
38. Apoptosis or programmed cell death?
39. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
40. Apoptosis in developing retinal tissue
41. Programmed cell death of retinal ganglion cells during experimental glaucoma
42. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis
43. TUNEL-positive ganglion cells in human primary open-angle glaucoma
44. Apoptosis of retinal ganglion cells in anterior ischemic optic neuropathy
45. Apoptosis, excitotoxicity, and neuropathology
46. New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration
47. Potential neuroprotective therapy for glaucomatous optic neuropathy
48. Is neuroprotection a viable therapy for glaucoma?
49. Excitatory amino acids as a final common pathway for neurologic disorders
50. Cell types using glutamate as a neurotransmitter in the vertebrate retina
51. The toxic effect of sodium L-glutamate on the inner layers of the retina
52. Glutamate-induced retinal degeneration in neonatal mice: Electron microscopy of the acutely evolving lesion
53. Reduced glutamate uptake by retinal glial cells under ischemic/hypoxic conditions
54. Glutamate neurotoxicity and diseases of the nervous system
55. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma
56. Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia
57. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia
58. Molecular basis of glutamate toxicity in retinal ganglion cells
59. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy
60. N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina
61. Assessment of Thy-1 mRNA levels as an index of retinal ganglion cell damage
62. Greater sensitivity of larger retinal ganglion cells to NMDA-mediated cell death
63. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy
64. Chronic low-dose glutamate is toxic to retinal ganglion cells: Toxicity blocked by memantine
65. A proposed role for excitotoxicity in glaucoma
66. Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder
67. Protection by eliprodil against excitotoxicity in cultured rat retinal ganglion cells
68. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells
69. Excitotoxic neurodegeneration induced by deprivation of oxygen and glucose in isolated retina
70. Biochemical and morphological analysis of non-NMDA receptor mediated excitotoxicity in chick embryo retina
71. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: Combined therapy and temporal course of protection
72. Trapping channel block of NMDA-activated responses by amantadine and memantine
73. Eliprodil hydrochloride
74. 3H]-ifenprodil binding sites: Implications for neuroprotection?
75. Systemic L-kynurenine administration partially protects against NMDA, but not kainate-induced degeneration of retinal ganglion cells, and reduces visual discrimination deficits in adults rats
76. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein
77. Effects of nilvadipine, a calcium antagonist, on rabbit ocular circulation and optic nerve head circulation in NTG subjects
78. Calcium channel blockers in the management of low-tension and open-angle glaucoma
79. Systemic calcium channel blockers and glaucoma
80. Lack of effect of calcium channel blockers on open-angle glaucoma
81. 2+ channel antagonists and neuroprotection from cerebral ischemia
82. The nerve of glaucoma!
83. 2+ channel antagonists on excitatory amino acid-evoked dopamine release
84. Protective effects of flunarizine on ischemic injury in the rat retina
85. 2+ channels and in gerbil global cerebral ischaemia
86. Nitric oxide: Physiology, pathophysiology, and pharmacology
87. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds
88. Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors
89. Retinal toxicity of nitric oxide released by administration of a nitric oxide donor in the albino rabbit
90. Free radicals in rabbit retina under ocular hyperpressure and functional consequences
91. Neuroprotection in relation to retinal ischemia and relevance to glaucoma
92. Effect of lipid peroxidation inhibition on retinal ganglion cell death
93. Nitric oxide synthase in the human glaucomatous optic nerve head
94. The role of neuronal and endothelial nitric oxide synthase in retinal excitotoxicity
95. Nitric oxide mediates excitotoxic and anoxic damage in rat retinal ganglion cells cocultured with astroglia
96. Nitric oxide synthase inhibition delays axonal degeneration and promotes the survival of axotomized retinal ganglion cells
97. Both the neuronal and inducible isoforms contribute to upregulation of retinal nitric oxide synthase activity by brain-derived neurotrophic factor
98. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma
99. Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic fibroblast growth factor
100. Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury
101. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells
102. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells: A quantitative in vivo study
103. Activation of NMDA receptors protects against glutamate neurotoxicity in the retina: Evidence for the involvement of neurotrophins
104. Free radical scavenging and inhibition of nitric oxide synthase potentiates the neurotrophic effects of brain-derived neurotrophic factor on axotomized retinal ganglion cells in vivo
105. Self-destructive and self-protective processes in the damaged optic nerve: Implications for glaucoma
106. Chronology of optic nerve head and retinal responses to elevated intraocular pressure
107. Checkpoints of dueling dimers foil death wishes
108. Overexpression of Bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia
109. Identification of the Bcl-2 family of genes in the rat retina
110. Apoptosis of retinal ganglion cells in glaucoma: An update of the molecular pathways involved in cell death
111. Caspases: Enemies within
112. Mitochondria and apoptosis
113. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration
114. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent
115. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: Potential neuroprotective effects of beta-blockers
116. Effects of betaxolol on light responses and membrane conductance in retinal ganglion cells
117. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects
118. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve